Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 8, 2004 - Issue 5
Submit an article Journal homepage
34
Views
6
CrossRef citations to date
0
Altmetric
Miscellaneous

Inhibition of cardiac cytochrome P450: a new approach to cardiac ischaemia and reperfusion damage

Sheila A Doggrell Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland. [email protected]
Pages 491-493 | Published online: 25 Feb 2005

Bibliography

  • LINK N, TANNER M: Coronary artery disease: part 1. Epidemiology and diagnosis. West. J. Med. (2001) 174:257–261.
  • GOTTLIEB RA: Cytochrome P450: a major player in reperfusion injury. Arch. Biochein. Biophys. (2003) 420:262–267.
  • GRANVILLE DJ, TASHAKKOR B, TAKEUCHI C et al: Reduction of ischemia and reperfusion myocardial damage by cytochrome P450 inhibitors. Proc. Natl. Acad. Sci. USA (2004) 101:1321–1326.
  • HALPERT J, NASLUND B, BETNER I: Suicide inactivation of rat liver cytochrome P450 by chloramphenicol in vivo and in vitro. Ma Phannacol (1983) 23:445–452.
  • HA-DUONG NT, MARQUES-SOARES C, DIJOLS S et al: Interaction of new sulfaphenazole derivates with human liver cytochrome P450 2Cs: structural determinants required for selective recognition by CYP 2CP and for inhibition of human CYP 2Cs. Arch. Biochein. Biophys. (2001) 394:189–200.
  • FLEMING I, MICHAELIS UR, BREDENKOTTER D et al.: Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ. Res. (2001) 88:44–51.
  • BYSANI GK, KENNEDY TP, KY N et al.: Role of cytochrome P450 in reperfusion injury of the rabbit lung. J. Gin. Invest. (1990) 86:1434–1441.
  • BANNING MM, CURTIS MJ: Protection by cimetidine, but not ranitidine, implies that H2 receptors do not mediate arrhythmogenesis in a rat model of regional ischaemia and reperfusion in vitro. Cardiovasc. Res. (1995) 30:705–710.
  • DOGGRELL SA, HANCOX JC: Is timing everything? Therapeutic potential of modulators of cardiac Na* transporters. Expert Opin. Investig. Drugs (2003) 12:1123–1142.
  • FLEMING I: Cytochrome P450 2C is anEDHF synthase in coronary arteries. Trends Cardiovasc. Med. (2000) 10:166–170.
  • PASSAUER J, BUSSEMAKER E, LASSIG G et al.: Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are sensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole. Clin. Sci. (2003) 105:513–518.
  • FICHTLSCHERER S, DIMMELER S, BREUER S et al.: Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation (2004) 109:178–183.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.